Acta Scientific Medical Sciences (ISSN: 2582-0931)

Ebook Volume 4 Issue 3

Psychosomatic Molecular Mechanisms of Metabolic Syndrome and Type 2 Diabetes. Part 4. A Recovery Strategy from Chronic Hypercapnia and Metabolic Syndrome-Related Disorders, (a Research Proposal)

András Sikter MD*

Internal Medicine, Municipal Clinic of Szentendre, Szentendre, Hungary, Europe

*Corresponding Author: András Sikter MD, Internal Medicine, Municipal Clinic of Szentendre, Szentendre, Hungary, Europe. E-mail:

Received: February 17, 2020; Published: February 29, 2020



  According to the hypothesis of the author, the Metabolic Syndrome and Type 2 Diabetes are mainly consequences of chronic low-grade hypercapnia and related intracellular acidosis. The altered pCO2 status changes the Intracellular Ion-Pattern and, consequently, the metabolism. The author has developed a recovery strategy based on his metabolic model, experiences, and data of literature. The primary goal is to increase the minute-ventilation to achieve low-grade hypocapnia (~ 35 mmHg on average) and to maintain it in the long run. As a consequence of the decreased pCO2 level - according to the hypothesis - an intracellular alkaline pH develops and results in increased metabolism, ATP production, and consequently, phosphate, Mg2+, K+, and Zn2+ influx into the cytosol. Serum Ca2+ levels may also decrease due to increased calcium and phosphate uptake into the 'hungry bones.' It is expected that both the carbohydrates and fats will be burned more intensively in mitochondria, which would also mean a decrease in insulin resistance, serum glucose, and lipid levels. The essence of the method is that regular daily administration of monobasic phosphate (H2PO4-) salts as fixed acids can increase respiratory minute volume and decrease the pCO2 level. It is advised to give these salts routinely in doses below the Recommended Dietary Allowance. After achieving the desired pCO2 level, it is advocated that an acidotic H2PO4-/ HPO42- salt mixture be titrated to maintain the low-grade hypocapnia. Preferably, the cations are provided by combinations of Mg2+, K+, and Ca2+. The amounts of ions to be administered can be determined by monitoring serum electrolytes. According to the hypothesis, this method could be particularly useful in diseases where elevated levels of pCO2 play a pathophysiological role.


  The author also proposes an improved method of Sodi-Pallarés; alternatively, it can be an infusion containing the combination of phosphate buffer, K+, Mg2+, Zn2+, and (possibly) other 'cytoplasm-builder' nutrients plus glucose and insulin. Theoretically, it could improve the metabolism of the chronically ill or insulin-resistant patients.

Keywords: Healing with Ion-Mixture Compositions; HPO42- as the Second Messenger of Insulin; Modified Method of Sodi-Pallarés; Momentary Intracellular Ion-Pattern Signaling



  1. Guerrero-Romero F and Rodríguez-Morán M. “Low serum magnesium levels and metabolic syndrome”. Acta Diabetologica 39.4 (2002): 209-213.
  2. Kao WH., et al. “Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study”. Archives of Internal Medicine 159.18 (1999): 2151 -2159.
  3. Simmons D., et al. “Hypomagnesaemia is associated with diabetes: Not pre-diabetes, obesity or the metabolic syndrome”. Diabetes Research and Clinical Practice 87.2 (2010): 261-266. 
  4. Barbagallo M and Dominguez LJ. “Magnesium and type 2 diabetes”. World Journal of Diabetes 6.10 (2015): 1152-1157. 
  5. Chatterjee R., et al. “Potassium and risk of Type 2 diabetes”. Expert Review of Endocrinology and Metabolism 6.5 (2011): 665-672.
  6. Rowe JW., et al. “Effect of experimental potassium deficiency on glucose and insulin metabolism”. Metabolism: Clinical and Experimental 29.6 (1980): 498-502.
  7. Honnorat J., et al., “Effects of diabetes type and treatment on zinc status in diabetes mellitus”. Biological Trace Element Research 32 (1992): 311-316.
  8. Al-Maroof RA and Al-Sharbatti S. “Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics”. Saudi Medical Journal 27.3 (2006): 344-350.
  9. Singh U. “Zinc in relation to type 1 and type 2 diabetes: An overview”. Journal of Applied and Natural Sciece 6.2 (2014): 898-903.
  10. Cruz KJC., et al. “Zinc and insulin resistance: Biochemical and molecular aspects”. Biological Trace Element Research 186.2 (2018): 407-412. 
  11. Håglin L. “Hypophosphataemia: cause of the disturbed metabolism in the metabolic syndrome”. Medical Hypotheses 56.6 (2001): 657-663. 
  12. Kalaitzidis R., et al. “Disturbances of phosphate metabolism: another feature of metabolic syndrome”. American Journal of Kidney Diseases 45.5 (2005): 851-458.
  13. DeFronzo RA and Lang R. “Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin”. The New England Journal of Medicine 303.22 (1980): 1259-1263.
  14. Zhou XJ., et al. “Phosphate depletion impairs insulin secretion by pancreatic islets”. Kidney International 39.1 (1991): 120-128.
  15. Lu Y., et al. “Serum amino acids in association with prevalent and incident Type 2 Diabetes in a Chinese population”. Metabolites 9.1 (2019): E14. 
  16. Bose S., et al. “Metabolic network control of oxidative phosphorylation: multiple roles of inorganic phosphate”. The Journal of Biologica Chemistry 278.40 (2003): 3955-3965.
  17. Yang J., et al. “Insulin-stimulated cytosol alkalinization facilitates optimal activation of glucose transport in cardiomyocytes”. American Journal of Physiology. Endocrinology and Metabolism 283.6 (2002): E1299-E1307.
  18. Lim El., et al. “Measuring the acute effect of insulin infusion on ATP turnover rate in human skeletal muscle using phosphorus-31 magnetic resonance saturation transfer spectroscopy”. NMR in Biomedicine 23.8 (2010): 952-957.
  19. Klip A., et al. “Insulin-induced cytoplasmic alkalinization and glucose transport in muscle cells”. The American Journal of Physiology 250.5 Pt1 (1986): C720-C728.
  20. Pesta DH., et al. “Hypophosphatemia promotes lower rates of muscle ATP synthesis”. FASEB Journal 30.10 (2016): 3378-3387.
  21. Huang X., et al. “The PI3K/AKT pathway in obesity and type 2 diabetes”. International Journal of Biological Sciences 14.11 (2018): 1483-1496.
  22. Beck L., et al. “Identification of a novel function of PiT1 critical for cell proliferation and independent of its phosphate transport activity”. The Journal of Biological Chemistry 284.45 (2009): 31363-31374. 
  23. DeFronzo RA., et al. “Effect of graded doses of insulin on splanchnic and peripheral potassium metabolism in man”. The American Journal of Physiology 238.5 (1980): E421-E427.
  24. Sweeney G and Klip A. “Regulation of the Na+/K+-ATPase by insulin: why and how?” Molecular and Cellular Biochemistry 182.1-2 (1998): 121-133.
  25. Taylor DJ., et al. “Effect of insulin on intracellular pH and phosphate metabolism in human skeletal muscle In vivo”. Clinical Science (London) 81.1 (1991): 123-128.
  26. Tenenhouse HS. “Regulation of phosphorus homeostasis by the type iia na/phosphate cotransporter”. Annual Review of Nutrition 25 (2005): 197-214.
  27. Brown TA. “Vitamin D analogs as anabolic agents”. Journal of Musculoskeletal and Neuronal Interactions 6.4 (2006): 341-343.
  28. Katai K., et al. “Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3”. The Biochemical Journal 343.Pt3 (1999): 705-712.
  29. Zittermann A. “Vitamin D in preventive medicine: are we ignoring the evidence?” The British Journal of Nutrition 89.5 (2003): 552-572.
  30. Harris SS. “Vitamin D in type 1 diabetes prevention”. The Journal of Nutrition 135.2 (2005): 323-325.
  31. Barbagallo M., et al. “Diabetes mellitus, hypertension and ageing: the ionic hypothesis of ageing and cardiovascular-metabolic diseases”. Diabetes and Metabolism 23.4 (1997): 281-294.
  32. Solati M., et al. “Oral magnesium supplementation in type II diabetic patients”. Medical Journal of the Islamic Republic of Iran 28 (2004): 67. 
  33. Gunasekara P., et al. “Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes”. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 4 (2011): 53-60.
  34. Kraut JA and Madias NE. “Consequences and therapy of the metabolic acidosis of chronic kidney disease”. Pediatric Nephrology 26.1 (2011): 19-28.
  35. Harris SS and Dawson-Hughes B. “No effect of bicarbonate treatment on insulin sensitivity and glucose control in non-diabetic older adults”. Endocrine 38.2 (2010): 221-226. 
  36. Park W., et al. “Serum phosphate levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword”. Diabetes Research and Clinical Practice 83.1 (2009): 119-125.
  37. Ditzel J and Lervang HH. “Disturbance of inorganic phosphate metabolism in diabetes mellitus: its impact on the development of diabetic late complications”. Current Diabetes Reviews 6.5 (2010): 323-333.
  38. Obeid OA. “Low phosphorus status might contribute to the onset of obesity”. Obesity Reviews 14.8 (2013): 659-664.
  39. Chun S., et al. “A High Phosphorus Diet Affects Lipid Metabolism in Rat Liver: A DNA Microarray Analysis”. PLoS One 11.5 (2016): e0155386. 
  40. Ayoub JJ., et al. “Effect of phosphorus supplementation on weight gain and waist circumference of overweight/obese adults: a randomized clinical trial”. Nutrition and Diabetes 5 (2015): e189. 
  41. Henningsen N and Jaedig S. “Composition to improve cellular metabolism”. (1986).
  42. Jaedig S and Henningsen NC. “Increased metabolic rate in obese women after ingestion of potassium, magnesium- and phosphate-enriched orange juice or injection of ephedrine”. International Journal of Obesity 15.6 (1991): 429-436.
  43. Jaedig S., et al. “Increased postprandial energy expenditure in obese women after peroral K- and Mg-phosphate”. Mineral Electrolyte and Metabolism 20.3 (1994): 147-152.
  44. Obeid O., et al. “Composition and use of macro-mineral glycemic response and reduce body weight”. U. S (2017).
  45. Obeid OA., et al. “Refeeding and metabolic syndromes: two sides of the same coin”. Nutrition and Diabetes 4 (2014): e120. 
  46. Allison SP., et al. “Insulin, glucose, and potassium in the treatment of congestive heart failure”. British Medical Journal 3.5828 (1972): 675-678.
  47. Benni JM and Patil PA. “Non-diabetic clinical applications of insulin”. Journal of Basic and Clinical Physiology and Pharmacology 27.5 (2016): 445-456.
  48. Wang D., et al. “Effects of intensive insulin therapy upon pancreatic β cell function in patients newly diagnosed with type II diabetes”. International Journal of Clinical and Experimental Medicine 8.1 (2015): 1391-1395.
  49. Szilvássy Z and Peitl B. “Gyógyszerösszetétel inzulin érzékenyítő hatás fokozására Composition of medicine for enhancing insulin sensitization”. Hungarian Patent Application (2013).
  50. Sakurai Y., et al. “Stimulation of muscle protein synthesis by long-term insulin infusion in severely burned patients”. Annals of Surgery 222.3 (1995): 283-297.


Citation: András Sikter. “Psychosomatic Molecular Mechanisms of Metabolic Syndrome and Type 2 Diabetes. Part 4. A Recovery Strategy from Chronic Hypercapnia and Metabolic Syndrome-Related Disorders, (a Research Proposal). Acta Scientific Medical Sciences 4.3 (2020): A41-A52.

Member In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US